Essential Premium

Biotech-Focused Hedge Funds Back Talawar’s Fast Moving SPAC Merger

RA Capital, Deep Track and other healthcare investors joined a $225 million PIPE supporting Talawar Therapeutics’ deal with JATT II, which found a merger partner just over two months after its IPO.

Alternatives in Wealth Management Forum | West Coast

September 29-30, 2026 | The Langham Huntington

Greenlight’s Flat June Masks Wild Swings Beneath the Surface

David Einhorn’s hedge fund gained just 20 basis points in June, but huge advances and steep declines among several of its largest holdings told a far more dramatic story.

Sponsored

Why Today’s Heightened Dispersion Suits a Systematic Approach

Hackensack Meridian’s Donna Snider Has Something Many CIOs Don’t: Liquidity

“Where others are overallocated to private markets, we have a lot of liquidity,” the ACA finalist says. “That’s a great opportunity we’re acting on.”

Related Content

Why Biotech Struggles to Finish What It Starts

Julie Segal

A Quick Windfall for Hedge Funds, Another Blow for a Biotech Company’s Early Backers

Stephen Taub

Opinion: When Workers’ Capital Funds Their Own Displacement

Angelo Calvello

1270 Avenue of the Americas, Suite 1100

New York, NY 10020

 

© Institutional Investor, LLC. All material subject to strictly enforced copyright laws. Please read our Terms and Conditions and Privacy Policy before using the site. Institutional Investor is part of Delinian.

 

| Unsubscribe

LinkedIn
X (Twitter)
Bluesky
Instagram